| CAS | 177943-89-4 |
| Sequence | 4,7,10-Tricarboxymethyl-1,4,7,10-tetraaza-cyclododecan-1-yl-acetyl-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-OH (Disulfide bond) |
| Sequence Single | 4,7,10-Tricarboxymethyl-1,4,7,10-tetraaza-cyclododecan-1-yl-acetyl-fCYwKTCT |
| Molecular Formula | C65H90N14O19S2 |
| Molecular Weight | 1435.65 |
| Synonyms | DOTATATE, DOTA-(Tyr3,Thr8)-Octreotide, DOTA-[Tyr3] Octreotide Acid (Octreotate) |
| Technology | Synthetic |
| Storage | -20°C, avoid light, cool and dry place |
| Application | Cancer Research |
| Description | DOTA-(Tyr3)-Octreotate also called DOTATATE, DOTA-(Tyr3,Thr8)-Octreotide, DOTA-[Tyr3] Octreotide Acid (Octreotate), is a DOTA-conjugated somatostatin analog for labeling with radiometals such as gallium-67 or gallium-68, indium-111, and yttrium-90. DOTA-(Tyr3)-Octreotate is a useful tool in receptor-mediated tumor imaging and peptide receptor-targeted radionuclide therapy. CAS-Number (net): 177943-88-3. |
| References | 1. Recombinant human prorenin from CHO cells: expression and purification. T.F.Holzman et al., J. Protein Chem., 9, 663 (1990) 2. Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro. A.Capello et al., Cancer Biother. Radiopharm., 18, 761 (2003) 3. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. R.Valkema et al., J. Nucl. Med., 46, 83S (2005) 4. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. W.A.Breeman et al., Eur. J. Nucl. Med. Mol. Imaging, 30, 917 (2003) 5. Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour. L.Kolby et al., Br. J. Cancer, 93, 1144 (2005) 6. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. Jong M, et, al. J Nucl Med. 2005 Jan;46 Suppl 1:13S-7S. 7. 68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy. Gains JE, et, al. Nucl Med Commun. 2020 Aug 10. 8. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Reubi JC, et, al. Eur J Nucl Med. 2000 Mar;27(3):273-82. |